CAH · Q2 2026 Earnings

Bullish

Cardinal Health

Reported February 5, 2026

30-second summary

Cardinal delivered Q2 non-GAAP EPS of $2.63 on revenue of $65.6B (+19% YoY), with Pharma & Specialty profit of $687M (+~28% YoY implied) and GMPD swinging to $37M from $18M last year — beating its own zero-YoY-growth guide. FY26 non-GAAP EPS was raised again to $10.15–$10.35 (from $9.65–$9.85), a $0.50 midpoint lift that is almost entirely operational, anchored to a 4-point raise in Pharma segment profit growth (16–19% → 20–22%) and the GMPD floor rising from "at least $140M" to "approximately $150M." The only quiet trim: GMPD revenue growth narrowed from 2–4% to 1–3%.

Headline numbers

EPS

Q2 FY2026

$2.63

Revenue

Q2 FY2026

$65.60B

+19.0% YoY

Gross margin

Q2 FY2026

3.6%

Operating margin

Q2 FY2026

1.1%

Key financials

Q2 FY2026

Metric	Q2 FY2026	YoY	Q1 FY2026	QoQ
Revenue	$65.60B	+19.0%	$64.00B	+2.5%
EPS	$2.63	—	$2.55	+3.1%
Gross margin	3.6%	—	3.6%	+3bps
Operating margin	1.1%	—	1.0%	+4bps

Guidance

Cardinal Health substantially raised full-year FY2026 non-GAAP EPS guidance to $10.15–$10.35 (+4.7% vs. prior) and boosted growth outlooks for pharma and other segments on strong Q2 execution, while reaffirming adjusted free cash flow guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Non-GAAP EPS	FY2026	$9.65 to $9.85	$10.15 to $10.35	+$0.50 to $0.50 (midpoint +$0.45, +4.7%)	Raised
Non-GAAP EPS growth	FY2026	17% to 20%	23% to 26%	+6 to +6 percentage points	Raised
Pharmaceutical and Specialty Solutions segment profit growth	FY2026	16% to 19%	20% to 22%	+4 to +3 percentage points (narrowed and raised)	Raised
Global Medical Products and Distribution segment profit	FY2026	at least $140 million	approximately $150 million	+$10 million	Raised
Other segment profit growth	FY2026	29% to 31%	33% to 35%	+4 to +4 percentage points	Raised
GMPD Revenue growth	FY2026	2% to 4%	1% to 3%	-1 to -1 percentage points	Lowered
Non-GAAP effective tax rate	FY2026	22% to 24%	21% to 23%	-1 to -1 percentage points (favorable)	Lowered
Diluted weighted average shares outstanding	FY2026	approximately 238 million	237 million to 238 million	~-1 million shares (range-based from point estimate)	Lowered

Reaffirmed unchanged this quarter: Adjusted free cash flow ($3.0 billion to $3.5 billion)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	YoY
Pharmaceutical and Specialty Solutions	$60.7B	+19.0%
Global Medical Products and Distribution	$3.3B	+3.0%
Other	$1.7B	+34.0%
Pharmaceutical and Specialty Solutions Segment Profit	$687 million	—
Global Medical Products and Distribution Segment Profit	$37 million	—
Other Segment Profit	$179 million	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026
Pharmaceutical and Specialty Solutions Segment Profit Margin	1.13%
Global Medical Products and Distribution Segment Profit Margin	1.14%
Other Segment Profit Margin	10.38%
Non-GAAP Operating Margin	1.34%
Share Repurchase Program	$750 million YTD

Management tone

GMPD turnaround skepticism (Q3 FY25) → GMPD validated, FY26 floor established (Q4 FY25) → Broad-based operational raise (Q1 FY26) → All five segments delivering double-digit profit growth simultaneously (Q2 FY26).

Three quarters ago GMPD was Cardinal's primary investor pain point and management spoke of "notable progress against the improvement plan." Two quarters ago it was "holding to our annual guidance" with confidence. Last quarter Q2 was explicitly flagged as zero-profit-growth on tariff drag. This quarter the segment doubled prior-year profit and the FY floor moved up $10M — and the language hardened to: "we're at levels of operational excellence that we've just not seen before... Those constraints are largely off, and we're really executing quite well." The shift is from recovery narrative to capability claim, and it removes a multi-year overhang that has compressed Cardinal's multiple.

The portfolio narrative has moved from "Pharma + GMPD turnaround + Other optionality" to genuine across-the-board strength. Q4 FY25 framing highlighted Other as contributing ">40% of enterprise earnings growth"; Q1 emphasized broad-based momentum; this quarter management explicitly anchored the story on "the balance of results across our portfolio as we achieve strong profit growth of at least double digits from all five of our operating segments." This is a different bull case — not "one segment carries the others" but "all five working at once" — and it justifies a higher multiple if sustained.

The M&A dependency has been quietly downgraded across three quarters. Q4 FY25 framed Solaris and the specialty MSO strategy as the strategic pillar; Q1 noted core organic strength was doing most of the lifting; this quarter management said "the core is strong and that our organic core investments and priorities continue to drive the business forward as well," explicitly noting M&A is ~8% of total growth. The implication: the bull thesis no longer requires the next deal to land cleanly. Combined with the $750M YTD repurchase (already at the full FY guide) and the unchanged $3.0–$3.5B FCF outlook, capital allocation is shifting toward buybacks earlier than the FY26 plan implied.

The hedging on demand sustainability has tightened. Last quarter management said they "are not assuming outsized utilization growth"; this quarter they explicitly factored stronger H2 demand into guidance "but we've not gone so far as to assume that the outsized demand we've seen so far will be what will be there." Translation: H2 guide bakes in some — not all — of Q2's strength, leaving residual upside if Q2's pace holds. The raise quality is therefore arguably understated.

Specialty has moved from "$50B revenue target by FY26" (Q1 framing) to explicit confidence: "we expect our specialty revenues will surpass $50 billion in fiscal 26." The platform language has firmed from aspiration to delivery, with the Solaris/Specialty Alliance footprint now described as the operating model rather than the integration project.

Recurring themes management leaned on this quarter:

Specialty ecosystem flywheel accelerating with MSO platforms, distribution, and biopharma solutions working in concertGMPD operational excellence and turnaround credibility solidifying with Cardinal Health brand gaining shareOther growth businesses (Nuclear, At-Home, Optifreight) showing double-digit organic growth with secular tailwindsBalance sheet flexibility returning earlier than expected, enabling opportunistic capital deploymentCore organic growth strength across all segments outpacing expectations despite M&A comparisonsTechnology and digitization investments (Synexis, Vantus HQ, Total View Insights) driving competitive moats

Risks management surfaced:

IRA, MFN pricing pressures and manufacturer WAC/rebate adjustments impacting revenueTariff headwinds particularly affecting GMPD profitabilityNormalization of Cardinal Health brand distributor buying patterns anticipated in Q3 after Q2 timing benefitDifficult Q3 theranostics comparisons from prior year product launchesGLP-1 oral adoption and channel mix volatility, though currently immaterial

Answers to last quarter's watch list

GMPD Q2 print versus the explicit zero-YoY-profit-growth guide. GMPD posted $37M in Q2 versus $18M in Q2 FY25 — more than double, against an explicit zero-growth guide. Management raised the FY26 floor from "at least $140M" to "approximately $150M" in direct response, and H1 GMPD profit ($83M) now sits at 55% of the new FY guide. Status: Resolved positively

Pharma segment profit growth in Q2. Pharma posted $687M segment profit on +19% YoY revenue, with the FY profit growth guide raised again from 16–19% to 20–22%. Management flagged Cardinal Health brand distributor buying-pattern timing that "anticipates offsetting in Q3," meaning some Q2 strength is borrowed forward — but the raised FY guide still implies sustained mid-to-high-teens growth in H2. The deceleration thesis was wrong direction; growth accelerated. Status: Resolved positively

Solaris close confirmation and first-quarter-of-ownership contribution. Solaris Health closed November 3, 2025, contributing two months to Q2. Management characterized the MSO contribution as consistent with expectations and noted Pharma segment growth was raised on core organic strength (M&A ~8% of total growth), so the FY guide does not require outsized Solaris contribution. Status: Resolved positively

Other segment profit dollars trajectory. Q2 Other segment profit was $179M (+52% YoY, +8% sequential vs. Q1's $166M), with the FY profit growth guide raised from 29–31% to 33–35%. The segment is comfortably above the implied $150M quarterly floor and accelerating. Status: Resolved positively

Whether the $50–75M FY tariff impact envelope expands. The extraction does not show an explicit re-statement or expansion of the $50–75M envelope; the GMPD revenue guide trim from 2–4% to 1–3% suggests some pressure remains, but the segment profit raise to ~$150M argues mitigation is holding. No widening was disclosed. Status: Continue monitoring

Biosimilar contribution disclosure. Cardinal did not break out biosimilar revenue or unit economics in the Q2 disclosure inputs. Status: Continue monitoring

What to watch into next quarter

Q3 Pharma deceleration vs. distributor buying-pattern timing. Management explicitly said they "anticipate offsetting in Q3" the Q2 Cardinal Health brand timing benefit. Watch whether Q3 Pharma segment profit growth stays above 15% YoY — a print below that level would confirm the timing reversal; a print above would suggest the H2 guide is conservative.

GMPD H2 cadence against the new ~$150M FY floor. H1 GMPD profit totals $83M, leaving ~$67M for H2 — a step-down from the H1 run-rate. Watch whether Q3 GMPD profit comes in above $30M, which would put further upward pressure on the floor.

Other segment Q3 dollars vs. the $179M Q2 print. With theranostics comps explicitly flagged as difficult in Q3 from prior-year product launches, watch whether Other segment profit holds above $160M.

Capital deployment after hitting full-year buyback at H1. Cardinal completed $750M YTD against a FY guide of "$750M ~for the year." Watch whether management announces incremental buybacks, an accelerated M&A pipeline, or holds powder — each signals a different read on the balance sheet and pipeline.

Whether the FY EPS guide is raised a third consecutive quarter at Q3. Two operational raises in two quarters establish a pattern; a third would harden the case that FY26 EPS lands above $10.35.

Sources

Cardinal Health Q2 FY2026 press release — https://www.sec.gov/Archives/edgar/data/721371/000072137126000004/a26q2_x123125xex991xnewsre.htm
Cardinal Health Q2 FY2026 earnings call (management commentary)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.